» Articles » PMID: 22956869

Nanotheranostics--a Review of Recent Publications

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2012 Sep 8
PMID 22956869
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Theranostics is referred to as a treatment strategy that combines therapeutics with diagnostics, aiming to monitor the response to treatment and increase drug efficacy and safety, which would be a key part of personalized medicine and require considerable advances in predictive medicine. Theranostics associates with both a diagnosis that tests patients for possible reactions to taking new medication and targeted drug delivery based on the test results. Emerging nanotechnology provides a great deal of opportunity to design and develop such combination agents, permitting the delivery of therapeutics and concurrently allowing the detection modality to be used not only before or after but also throughout the entire treatment regimen. The introduction of nanotheranostics into routine health care has still a long way to go, since evaluations on cytotoxicity, genotoxicity, and immunotoxicity of prospective nanotheranostics, demonstration of cost-effectiveness, and availability of appropriate accessible testing systems are still required. An extensive review, from a chemistry point of view, of the recent development of nanotheranostics and its in vitro and in vivo applications are herein presented.

Citing Articles

Recent nanotheranostic approaches in cancer research.

Gupta D, Roy P, Sharma R, Kasana R, Rathore P, Gupta T Clin Exp Med. 2024; 24(1):8.

PMID: 38240834 PMC: 10799106. DOI: 10.1007/s10238-023-01262-3.


Nanotheranostics: The Fabrication of Theranostics with Nanoparticles and their Application to Treat the Neurological Disorders.

Singh A, Patel A, Chaudhary H, Yadav K, Minocha N Recent Pat Nanotechnol. 2023; 19(1):17-34.

PMID: 37464820 DOI: 10.2174/1872210517666230718115651.


α-Fe O @Ag and Fe O @Ag Core-Shell Nanoparticles: Green Synthesis, Magnetic Properties and Cytotoxic Performance.

Sarani M, Hamidian K, Barani M, Adeli-Sardou M, Khonakdar H ChemistryOpen. 2023; 12(6):e202200250.

PMID: 37260410 PMC: 10235882. DOI: 10.1002/open.202200250.


Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.

Chakraborty K, Mondal J, An J, Park J, Lee Y Pharmaceutics. 2023; 15(3).

PMID: 36986832 PMC: 10054444. DOI: 10.3390/pharmaceutics15030971.


A detailed insight of the tumor targeting using nanocarrier drug delivery system.

Batool S, Sohail S, Din F, Alamri A, Alqahtani A, Alshahrani M Drug Deliv. 2023; 30(1):2183815.

PMID: 36866455 PMC: 10191068. DOI: 10.1080/10717544.2023.2183815.


References
1.
Wagner D, Delk N, Lukianova-Hleb E, Hafner J, Farach-Carson M, Lapotko D . The in vivo performance of plasmonic nanobubbles as cell theranostic agents in zebrafish hosting prostate cancer xenografts. Biomaterials. 2010; 31(29):7567-74. PMC: 2924909. DOI: 10.1016/j.biomaterials.2010.06.031. View

2.
Moon G, Choi S, Cai X, Li W, Cho E, Jeong U . A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release. J Am Chem Soc. 2011; 133(13):4762-5. PMC: 3073071. DOI: 10.1021/ja200894u. View

3.
Foy S, Manthe R, Foy S, Dimitrijevic S, Krishnamurthy N, Labhasetwar V . Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano. 2010; 4(9):5217-24. PMC: 2947615. DOI: 10.1021/nn101427t. View

4.
Rastogi R, Gulati N, Kotnala R, Sharma U, Jayasundar R, Koul V . Evaluation of folate conjugated pegylated thermosensitive magnetic nanocomposites for tumor imaging and therapy. Colloids Surf B Biointerfaces. 2010; 82(1):160-7. DOI: 10.1016/j.colsurfb.2010.08.037. View

5.
Nurunnabi M, Cho K, Choi J, Huh K, Lee Y . Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials. 2010; 31(20):5436-44. DOI: 10.1016/j.biomaterials.2010.03.057. View